Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership7,782 shares
Latest Disclosed Value $ 502,951
Alps Advisors Inc reports 29.87% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 7,782 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $502,951 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 5,992 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 29.87% during the quarter. The current value of the position is $556,646 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 7,782 1,790 29.87 503 24.57 0.0022
2026-02-12 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 5,992 66 1.11 403 -7.14 0.0023
2025-11-05 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 5,926 170 2.95 435 45.15 0.0024
2025-08-11 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 5,756 70 1.23 299 -17.40 0.0017
2025-04-30 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 5,686 -1 -0.02 363 33.58 0.0021
2025-02-13 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 5,687 0 0.00 272 -16.62 0.0017
2024-11-12 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 5,687 -2,701 -32.20 326 -25.97 0.0022
2024-08-13 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 8,388 -45 -0.53 439 27.99 0.0030
2024-05-14 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 8,433 -81 -0.95 343 9.24 0.0024
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 8,514 -486 -5.40 315 -8.45 0.0025
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 9,000 9,000 344 0.0029
2023-05-10 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -7,638 -100.00 0 -100.00
2023-02-14 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 7,638 -31 -0.40 435 43.23 0.0039
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 7,669 7,669 303 0.0029
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -8,959 -100.00 0 -100.00
2022-02-09 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 8,959 180 2.05 360 0.84 0.0041
2021-11-15 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 8,779 8,779 357 0.0034
2020-02-07 2019-12-31 13F HALOZYME THERAPE COMMON STOCK 40637H109 0 -291,765 -100.00 0 -100.00
2019-11-04 2019-09-30 13F HALOZYME THERAPE COMMON STOCK 40637H109 291,765 -11,592 -3.82 4,525 -13.18 0.0352
2019-08-07 2019-06-30 13F HALOZYME THERAPE COMMON STOCK 40637H109 303,357 -46,953 -13.40 5,212 -7.59 0.0386
2019-05-01 2019-03-31 13F HALOZYME THERAPE COMMON STOCK 40637H109 350,310 -10,698 -2.96 5,640 6.78 0.0399
2019-02-04 2018-12-31 13F HALOZYME THERAPE COMMON STOCK 40637H109 361,008 77,631 27.39 5,282 2.58 0.0410
2018-10-25 2018-09-30 13F HALOZYME THERAPE COMMON STOCK 40637H109 283,377 53,811 23.44 5,149 32.95 0.0338
2018-08-02 2018-06-30 13F/A-2 Halozyme Therapeutics COMMON STOCK 40637H109 229,566 14,709 6.85 3,873 -7.98 0.0253
2018-07-31 2018-06-30 13F/A-1 Halozyme Therapeutics COMMON STOCK 40637H109 157,748 -71,818 3,196 0.0204
2018-07-25 2018-06-30 13F Halozyme Therapeutics COMMON STOCK 40637H109 157,748 -57,109 3,196
2018-05-01 2018-03-31 13F Halozyme Therapeutics COMMON STOCK 40637H109 214,857 57,109 36.20 4,209 31.70 0.0335
2018-02-20 2017-12-31 13F/A-1 Halozyme Therapeutics COMMON STOCK 40637H109 157,748 17,984 12.87 3,196 31.63 0.0221
2018-02-05 2017-12-31 13F Halozyme Therapeutics COMMON STOCK 40637H109 157,748 17,984 3,196
2017-11-03 2017-09-30 13F Halozyme Therapeutics COMMON STOCK 40637H109 139,764 13,556 10.74 2,428 50.06 0.0172
2017-08-03 2017-06-30 13F Halozyme Therapeutics COMMON STOCK 40637H109 126,208 14,807 13.29 1,618 12.05 0.0113
2017-05-12 2017-03-31 13F Halozyme Therapeutics COMMON STOCK 40637H109 111,401 -13,037 -10.48 1,444 17.49 0.0100
2017-01-24 2016-12-31 13F Halozyme Therapeutics Common Stock 40637H109 124,438 -40,544 -24.57 1,229 -38.33 0.0091
2016-11-02 2016-09-30 13F Halozyme Therapeutic Common Stock 40637H109 164,982 -16,371 -9.03 1,993 27.35 0.0163
2016-07-27 2016-06-30 13F Halozyme Therapeutic Common Stock 40637H109 181,353 38,688 27.12 1,565 15.84 0.0139
2016-05-10 2016-03-31 13F Halozyme Therapeutic Common Stock 40637H109 142,665 -25,974 -15.40 1,351 -53.78 0.0139
2016-02-05 2015-12-31 13F Halozyme Therapeutic Common Stock 40637H109 168,639 -30,553 -15.34 2,923 -89.07 0.0285
2015-11-13 2015-09-30 13F Halozyme Therapeutic Common Stock 40637H109 199,192 72,873 57.69 26,751 837.97 0.0282
2015-08-12 2015-06-30 13F HALOZYME THERAPEUTICS Common Stock 40637H109 126,319 64,009 102.73 2,852 220.45 0.0243
2015-05-15 2015-03-31 13F HALOZYME THERAPEUTICS Common Stock 40637H109 62,310 62,310 890 0.0073
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.